Citigroup Inc Compugen LTD Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Compugen LTD stock. As of the latest transaction made, Citigroup Inc holds 1,610 shares of CGEN stock, worth $2,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,610

Holding current value

$2,640

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$1.68 - $2.52 $2,704 - $4,057	1,610 New	1,610 $2,000
Q2 2023 Aug 10, 2023	SELL	$0.57 - $1.38 $45,475 - $110,099	-79,782 Reduced 74.49%	27,316 $31,000
Q1 2023 May 11, 2023	BUY	$0.68 - $1.11 $64,678 - $105,578	95,116 Added 793.82%	107,098 $74,000
Q4 2022 Feb 09, 2023	SELL	$0.58 - $1.2 $29,622 - $61,287	-51,073 Reduced 81.0%	11,982 $8,000
Q3 2022 Nov 10, 2022	BUY	$0.66 - $2.32 $40,732 - $143,181	61,716 Added 4609.11%	63,055 $41,000
Q2 2022 Aug 10, 2022	SELL	$1.57 - $3.33 $97,837 - $207,515	-62,317 Reduced 97.9%	1,339 $2,000
Q1 2022 May 12, 2022	SELL	$2.76 - $4.64 $36,738 - $61,763	-13,311 Reduced 17.29%	63,656 $205,000
Q4 2021 Feb 10, 2022	SELL	$4.09 - $7.16 $31,223 - $54,659	-7,634 Reduced 9.02%	76,967 $331,000
Q3 2021 Nov 10, 2021	BUY	$5.8 - $8.02 $490,685 - $678,500	84,601 New	84,601 $505,000

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.3M

Call Options Held

191K

Put Options Held

135K

Silverarc Capital Management, LLC

1.5M
Shares

$2.46 Million
0.72% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

1.29M
Shares

$2.11 Million
0.0% of portfolio
Taylor Frigon Capital Management LLC

1.2M
Shares

$1.97 Million
1.09% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

1.09M
Shares

$1.79 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

1.02M
Shares

$1.67 Million
0.0% of portfolio

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $142M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account